Retatrutide GLP-3 15 mg

Retatrutide GLP-3 15 mg at a glance

Retatrutide is a synthetic peptide described in the scientific literature as a triple agonist at the receptors for GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide 1) and glucagon. The sequence is derived from native GIP and carries a lipidated side chain that the literature associates with albumin binding and an extended half-life. As the first widely published representative of the triple agonist class, Retatrutide serves in basic research as a reference compound for studying simultaneously activated incretin and glucagon signalling pathways.

• Nominal amount: 15 mg
• Batch-specific certificate of analysis (COA)
• Documented assignment of product and batch
• Analytical data on the stated identity and purity according to the COA

The decisive reference is always the COA of the batch actually shipped, not a general purity figure quoted on a product page.

Product details

Short molecular profile:

• Class: synthetic, lipidated peptide based on GIP
• Mechanism described in the literature: agonism at the GIP, GLP-1 and glucagon receptors
• Typical research fields: receptor pharmacology, incretin and glucagon signalling pathways, energy metabolism in cell and animal models

In research models, Retatrutide is examined with regard to the combined activation of GIP, GLP-1 and glucagon receptors and the cellular and metabolic signalling pathways associated with it. Published work addresses, among other topics, the receptor selectivity and balance of the molecule at the three target receptors, downstream signalling cascades in cell models, and comparative questions concerning mono-, dual- and triple agonists of the incretin class. Reproducible laboratory work rests on batch-specific identity and purity documentation together with appropriate storage of the material.

What does “GLP-3” mean?

“GLP-3” is not a hormone of its own but a widely used informal term for the third generation of incretin-based research peptides: GLP-1 mono-agonists (for example semaglutide) were followed by dual GIP/GLP-1 agonists (for example tirzepatide), and then by Retatrutide as the triple agonist that additionally addresses the glucagon receptor. Searches for “GLP-3” or “GLP3 peptide” usually refer to Retatrutide as research material. Peptélia stocks Retatrutide GLP-3 in 5, 10, 15 and 20 mg as well as in a capsule formulation, each with a batch-specific COA.

Retatrutide GLP-3 from Peptélia

Retatrutide GLP-3 15 mg is available from Peptélia as research reference material – the largest nominal amount, intended for more extensive experimental series. Every batch is analysed by HPLC in our own laboratory, and the corresponding certificate of analysis can be viewed before purchase. Further nominal amounts are Retatrutide GLP-3 5 mg, Retatrutide GLP-3 10 mg and Retatrutide GLP-3 20 mg (the latter also in packs of 3, 5 or 10 vials); all variants are listed in the Retatrutide (GLP-3) category.

Ordering from Peptélia

• Select the pack size above: 1, 3, 5 or 10 vials — the larger the pack, the lower the price per vial
• Dispatched from Germany on the next business day
• Delivery times vary by destination
• Free shipping on orders over €100
• Bacteriostatic water for reconstitution included with every order
• Batch certificate of analysis viewable before purchase
• Discreet, unbranded packaging

Quality & documentation

Every batch ships with a batch-specific certificate of analysis (COA). Purity is determined by HPLC; identity and analytical data are provided for complete laboratory documentation.

Important notice

All substances offered by Peptélia are intended exclusively for scientific use in the laboratory (research use only). They are not medicinal products, not food supplements and not cosmetics. Use in humans or animals, as well as any diagnostic or therapeutic use, is expressly excluded.

Further reading: Research overview of Retatrutide in the peptide library

For research use only. Not for use in or on the human body.